Insys Therapeutics, Inc. (NASDAQ:INSY) Upgraded to Strong-Buy at Zacks Investment Research

Insys Therapeutics, Inc. (NASDAQ:INSY) was upgraded by Zacks Investment Research from a “sell” rating to a “strong-buy” rating in a note issued to investors on Wednesday, July 12th. The brokerage currently has a $15.00 target price on the specialty pharmaceutical company’s stock. Zacks Investment Research‘s price target would suggest a potential upside of 68.35% from the company’s current price.

According to Zacks, “Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. It is engaged in the development and commercialization of pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company’s cancer-supportive care and cancer therapy product candidates include Fentanyl sublingual spray and Dronabinol SG capsule. Insys Therapeutics, Inc. is based in Phoenix, Arizona. “

A number of other brokerages also recently weighed in on INSY. Royal Bank Of Canada set a $16.00 price target on Insys Therapeutics and gave the stock a “buy” rating in a research report on Saturday, June 3rd. BidaskClub raised Insys Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, July 8th. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Insys Therapeutics in a research report on Tuesday, July 4th. Piper Jaffray Companies downgraded Insys Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $20.00 to $10.00 in a research report on Wednesday, May 10th. Finally, Jefferies Group LLC reissued a “buy” rating and set a $14.00 price target on shares of Insys Therapeutics in a research report on Friday, June 9th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $13.25.

Shares of Insys Therapeutics (NASDAQ INSY) traded down 1.66% on Wednesday, hitting $8.91. The stock had a trading volume of 565,643 shares. Insys Therapeutics has a 12-month low of $8.70 and a 12-month high of $18.50. The company’s 50-day moving average price is $11.86 and its 200 day moving average price is $11.42. The firm’s market cap is $647.72 million.

Insys Therapeutics (NASDAQ:INSY) last released its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.12. The business had revenue of $42.60 million for the quarter, compared to the consensus estimate of $36.90 million. Insys Therapeutics had a negative return on equity of 3.02% and a negative net margin of 9.63%. Insys Therapeutics’s quarterly revenue was down 38.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.13 earnings per share. On average, equities research analysts forecast that Insys Therapeutics will post ($0.29) earnings per share for the current fiscal year.

WARNING: “Insys Therapeutics, Inc. (NASDAQ:INSY) Upgraded to Strong-Buy at Zacks Investment Research” was posted by Community Financial News and is the property of of Community Financial News. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.com-unik.info/2017/08/12/insys-therapeutics-inc-nasdaqinsy-rating-increased-to-strong-buy-at-zacks-investment-research-updated-updated-updated.html.

In related news, Director Rohit Vishnoi purchased 4,000 shares of the business’s stock in a transaction that occurred on Thursday, June 1st. The stock was acquired at an average cost of $14.14 per share, for a total transaction of $56,560.00. Following the completion of the purchase, the director now owns 4,000 shares in the company, valued at approximately $56,560. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Steven J. Meyer purchased 8,000 shares of the business’s stock in a transaction that occurred on Thursday, May 18th. The stock was bought at an average price of $12.21 per share, with a total value of $97,680.00. Following the completion of the purchase, the director now owns 52,083 shares of the company’s stock, valued at approximately $635,933.43. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 27,400 shares of company stock valued at $317,150. Corporate insiders own 67.90% of the company’s stock.

Several large investors have recently modified their holdings of INSY. SG Americas Securities LLC purchased a new position in shares of Insys Therapeutics during the second quarter valued at approximately $138,000. American International Group Inc. increased its position in shares of Insys Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 14,462 shares of the specialty pharmaceutical company’s stock valued at $152,000 after buying an additional 953 shares during the last quarter. BNP Paribas Arbitrage SA increased its position in shares of Insys Therapeutics by 213.2% in the second quarter. BNP Paribas Arbitrage SA now owns 13,133 shares of the specialty pharmaceutical company’s stock valued at $166,000 after buying an additional 8,940 shares during the last quarter. UBS Asset Management Americas Inc. purchased a new position in shares of Insys Therapeutics during the first quarter valued at approximately $172,000. Finally, Janney Montgomery Scott LLC purchased a new position in shares of Insys Therapeutics during the first quarter valued at approximately $188,000. Institutional investors own 28.15% of the company’s stock.

Insys Therapeutics Company Profile

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Get a free copy of the Zacks research report on Insys Therapeutics (INSY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about Insys Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Insys Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit